4Q Financial Reports: Schering-Plough

Schering-Plough

4Q Revenues: $2.3 billion (+6%)

4Q Earnings: $126 million (loss of $834 million 4Q2004)

FY Revenues: $9.5 billion (+15%)

FY Earnings: $269 million (loss of $947 million FY2004)

Comments: Sales increase for 4Q was driven by the growth of prescription pharmaceuticals, led by Peg-Intron, Rebetol, Nasonex and Remicade. Peg-Intron sales were $214 million, up 55%. Rebetol sales were $94 million, up 93%. Nasonex sales were $185 million, up 27%. Remicade sales were $251 million, up 19%. Pharma revenues do not include sales of the cholesterol products marketed in partnership with Merck. Global cholesterol joint venture sales, which include Vytorin and Zetia, totaled approximately $755 million for the quarter. R&D spending was $474 million for the quarter, up 17%.